Floatz logo

Meropenem

Biliary Atresia

Children's Hospital of Fudan UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Biliary Atresia cohort.

Asset / SponsorPhaseRating
MELOXIDOLOR
Yonsei University
Phase 4BB
Pentoxifylline
Baylor College of Medicine
Phase 2CCC
Vancomycin
Sacramento Pediatric Gastroenterology
Phase 1CC
CEFACLOR ANHYDROUS
Children's Hospital of Fudan University
N/AD
IMIPENEM
Children's Hospital of Fudan University
N/AD

View all 11 →

Same molecule, other indications

Meropenem is also rated in:

Pseudomonas infectionDormant
B
Indicative ·
62 / 100
View asset →
pneumoniaDormant
B
Indicative ·
62 / 100
View asset →
sclerosing cholangitisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →